We'll know more about the company's medium-term prospects by the end of the year.

CRISPR technology, targeting genetic diseases and cancer, may bring major biotech stock growth. CRISPR Therapeutics and Intellia show progress with clinical trials and big pharma partnerships.

CRISPR technology may soon lead to major stock growth in genomics. CRISPR therapies target diseases with genetic editing either inside or outside the body. Beam, CRISPR Therapeutics, Caribou, and ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics ...

Wondering if CRISPR Therapeutics at around US$51.22 is pricing in too much hope or leaving room on the table? This article walks through what the current share price may be implying about the company.

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...